CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation
Open Access
- 4 June 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2786-2792
Abstract
Autologous stem cell transplantation (ASCT) with maintenance lenalidomide remains the mainstay of consolidation therapy for eligible patients with multiple myeloma, but preventing disease relapse remains a critical unmet need. Here, we investigated whether immunosuppressive myeloid populations in bone marrow correlated with ASCT outcomes. We identified a subset of CD64+CD169+CD163+ macrophages that expressed CSF-1R, PD-L1, and CD155 and were expanded in patients who relapsed after ASCT. Using a preclinical ASCT model with suboptimal endogenous antimyeloma activity, we demonstrated that although neither CSF-1R inhibition nor lenalidomide monotherapy significantly improved outcomes, their combination synergistically attenuated disease progression and prolonged survival. Single-cell RNA sequencing revealed that lenalidomide expanded natural killer (NK)–like CD8+ T cells but paradoxically also increased the frequency of Csf1r+ macrophages. Cell-cell communication analyses identified Csf1r+ macrophages as suppressors of these NK- and effector-like phenotypically exhausted (Tphex) CD8 T-cell populations through CD94/NKG2A and PD-L1/PD-1, respectively. CSF-1R blockade depleted these immunosuppressive macrophages, which correlated with decreased expression of inhibitory receptors and enhanced expression of activation markers in Tphex. Given the US Food and Drug Administration approval of axatilimab for chronic graft-versus-host disease, combining CSF-1R blockade with lenalidomide maintenance represents a readily testable strategy to improve progression-free survival after ASCT.Keywords
This publication has 25 references indexed in Scilit:
- Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 2024
- CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axisNature Cancer, 2023
- NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancerCancer Cell, 2022
- Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaNew England Journal of Medicine, 2022
- IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumorsMolecular Therapy, 2022
- Therapeutic effects of CSF1R-blocking antibodies in multiple myelomaLeukemia, 2017
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer TherapyCancer Cell, 2014
- Tissue-Resident Macrophages Self-Maintain Locally throughout Adult Life with Minimal Contribution from Circulating MonocytesImmunity, 2013
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory PropertiesCell Metabolism, 2007